Table 4 Patients characteristics and symptomatic DVT
DVD(-) | DVT(+) | ||||
|---|---|---|---|---|---|
Characteristics | n = 318 | n = 56 | p | ||
Age | 68.2 ± 11.6 | ( 25-90 ) | 74.5 ± 7.8 | (45-86) | <0.00001 |
   Age≧75 yr | 106 | 32 | 0.001 | ||
   Age < 75 yr | 212 | 24 | |||
Gender(male/female) | 60/258 | 5/51 | 0.070 | ||
BMI(Kg/m2) | 24.7 ± 4.2 | (13.7-41.4) | 25.8 ± 3.8 | (20.1-35.1) | 0.088 |
   BMI≧30 | 37 | 10 | 0.195 | ||
   BMI < 30 | 281 | 46 | |||
Risk factors | 176(55.3%) | 38(67.9%) | 0.081 | ||
TKA/THA | 125/193 | 35/21 | 0.001 | ||
OA/RA | 273/46 | 48/7 | 0.697 | ||
Seroconvertion of IgG-class Anti-PF4/heparin Ab | 54(17.0%) | 20(35.7%) | 0.001 | ||
Treatment | |||||
   UFH | 89 | (27.7%) | 16 | (28.6%) | 0.890 |
   LMWH | 81 | (25.5%) | 14 | (25.0%) | 0.940 |
   Fondaparinux | 73 | (23.0%) | 8 | (14.3%) | 0.146 |
   Others | 37 | (11.6%) | 13 | (23.2%) | |
Aspirin | 31 | (9.7%) | 12 | (21.4%) | |
Warfarin | 5 | (1.6%) | 0 | ||
Cilostazol | 26 | (8.2%) | 11 | (19.6%) | |
   No medication | 39 | (12.3%) | 5 | (8.9%) | 0.475 |